Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Review proposal consultation

Stakeholder matrix (MSWord 35 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination  information

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document (PDF 291 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 250 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): consultee and commentator comments on the ACD

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Roche Products

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Roche Products (PDF 770 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome (PDF 101 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer (PDF 198 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing (PDF 24 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists (PDF 3.6 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO) (PDF 324 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Department of Health

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Department of Health (PDF 22 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NHS outer north east London cluster

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NHS outer north east London cluster (PDF 135 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service (PDF 315 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Southampton Health Technology Assessments Centre

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Southampton Health Technology Assessments Centre (PDF 30 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): comments on the ACD received from the public through the NICE website

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation document information

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer (including review of technology appraisal no. 91 and technology appraisal no. 222) information

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal announcement information

Appeals received

Appeals received (PDF 300 KB)

Initial scrutiny letter - Pharma Mar

Initial scrutiny letter - Pharma Mar (PDF 285 KB)

Response to scrutiny letter

Response to scrutiny letter (PDF 180 KB)

Final scrutiny letter

Final scrutiny letter (PDF 104 KB)

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (including reviews of technology appraisal guidance 91 and 222): notice of appeal information

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination information

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report information

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report (PDF 2.29 MB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination document

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination document (PDF 542 KB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appraisal consultation information

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appraisal consultation document information

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report information

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): evaluation report (PDF 10.74 MB)

Ovarian Cancer Topotecan Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel Trabectedin and Gemcitabine (Review) Assessment Report - Consultation

Ovarian Cancer Topotecan Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel Trabectedin and Gemcitabine (Review) Assessment Report - Consultation (PDF 6.08 MB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final protocol

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final protocol (PDF 330 KB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final scope (post CIM)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final scope (post CIM) (PDF 67 KB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final matrix

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final matrix (PDF 66 KB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and commentator comments on the draft scope

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and commentator comments on the draft scope (PDF 278 KB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): equality impact assessment form - scoping

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): equality impact assessment form - scoping (PDF 29 KB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft scope

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft scope (PDF 74 KB)

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft matrix

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft matrix (PDF 66 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): evaluation report

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Pre-meeting briefing

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Pre-meeting briefing (PDF 528 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report (PDF 453 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report - factual accuracy check

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Evidence Review Group report - factual accuracy check (PDF 57 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer submission - Roche

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer submission - Roche (PDF 2.6 MB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Clarification

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NICE clarification letter

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NICE clarification letter (PDF 85 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer response to the NICE clarification letter

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Manufacturer response to the NICE clarification letter (PDF 350 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Patient group, professional group and NHS organisation submission statements

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NCRI Gynaecological CSG/RCP/RCR/ACP/JCCO

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NCRI Gynaecological CSG/RCP/RCR/ACP/JCCO (PDF 282 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome (PDF 107 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovarian Cancer Action

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovarian Cancer Action (PDF 100 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing (PDF 6.9 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists (PDF 52 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer (PDF 92 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Expert written personal statements

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Marcia Hall

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Marcia Hall (PDF 38 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sharon Tate

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sharon Tate (PDF 45 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sarah Blagden

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Dr Sarah Blagden (PDF 45 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Louise Bayne

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Louise Bayne (PDF 26 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Rajinder Nijjar

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Rajinder Nijjar (PDF 52 KB)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ms Oge Chesa

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010